Literature DB >> 2894296

Dynorphin A inhibits and naloxone increases the electrically stimulated release of oxytocin but not vasopressin from the terminals of the neural lobe.

C A Bondy1, H Gainer, J T Russell.   

Abstract

Oxytocin release from the rat neurohypophysis is under endogenous opioid inhibition. It has recently been established that dynorphin precursor-derived peptides are colocalized with vasopressin (VP) in the secretory granules in nerve terminals of the neural lobe, and that the opiate receptors in the neural lobe are restricted to the kappa-subtype. Therefore, we hypothesized that dynorphin, which is copackaged and thus coreleased with VP, is the endogenous opioid that inhibits release from neighboring oxytocin (OT) terminals. To test this hypothesis we examined the effects of dynorphin-(1-8), dynorphin-(1-17), and naloxone on the electrically stimulated release of OT and VP from isolated rat neurointermediate lobes throughout a range of stimulus frequencies. Both dynorphin-(1-8) and -(1-17) (2 microM) produced a substantial reduction in OT release during a 4-Hz stimulus, and this effect was abolished by naloxone (10 microM). Neither form of dynorphin, however, affected OT secretion at a stimulus frequency of 12 or 30 Hz at concentrations up to 10 microM. Naloxone (10 microM) by itself did not affect OT release during the 4-Hz stimulus, but it produced a substantial increase in OT release at a stimulus frequency of 12 Hz. In contrast, neither form of dynorphin produced inhibition, nor did naloxone augment VP secretion at any frequency tested. Frequency-dependent secretion curves (4, 8, 12, 20, and 30 Hz) for OT and VP in the presence and absence of naloxone indicated that the degree of naloxone augmentation of OT release at a given stimulus frequency was positively correlated with the amount of VP release at that frequency. These data support the hypothesis that dynorphin released in parallel with VP during in vitro stimulations of the rat neurohypophysis simultaneously inhibits stimulated OT release.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894296     DOI: 10.1210/endo-122-4-1321

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Voltage-dependent kappa-opioid modulation of action potential waveform-elicited calcium currents in neurohypophysial terminals.

Authors:  Cristina M Velázquez-Marrero; Héctor G Marrero; José R Lemos
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

2.  Naloxone potentiates the release of oxytocin induced by systemic administration of cholecystokinin without enhancing the electrical activity of supraoptic oxytocin neurones.

Authors:  G Leng; R E Dyball; S A Way
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

Review 3.  Coexisting peptides in hypothalamic neuroendocrine systems: some functional implications.

Authors:  C A Bondy; M H Whitnall; L S Brady; H Gainer
Journal:  Cell Mol Neurobiol       Date:  1989-12       Impact factor: 5.046

Review 4.  Modulation/physiology of calcium channel sub-types in neurosecretory terminals.

Authors:  José R Lemos; Sonia I Ortiz-Miranda; Adolfo E Cuadra; Cristina Velázquez-Marrero; Edward E Custer; Taimur Dad; Govindan Dayanithi
Journal:  Cell Calcium       Date:  2012-02-17       Impact factor: 6.817

Review 5.  Gene expression and chemical diversity in hypothalamic neurosecretory neurons.

Authors:  B Meister
Journal:  Mol Neurobiol       Date:  1993       Impact factor: 5.590

6.  Peptides and transmitter enzymes in hypothalamic magnocellular neurons after administration of hyperosmotic stimuli: comparison between messenger RNA and peptide/protein levels.

Authors:  B Meister; R Cortés; M J Villar; M Schalling; T Hökfelt
Journal:  Cell Tissue Res       Date:  1990-05       Impact factor: 5.249

7.  Intracellular calcium and hormone release from nerve endings of the neurohypophysis in the presence of opioid agonists and antagonists.

Authors:  G Dayanithi; E L Stuenkel; J J Nordmann
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

8.  Morphine tolerance and inhibition of oxytocin secretion by kappa-opioids acting on the rat neurohypophysis.

Authors:  J A Russell; J E Coombes; G Leng; R J Bicknell
Journal:  J Physiol       Date:  1993-09       Impact factor: 5.182

9.  Effects of the selective kappa-opioid agonist U50,488 upon the electrical activity of supraoptic neurones in morphine-tolerant and morphine-naive rats.

Authors:  K M Pumford; J A Russell; G Leng
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

10.  kappa-opioid regulation of neuronal activity in the rat supraoptic nucleus in vivo.

Authors:  C H Brown; M Ludwig; G Leng
Journal:  J Neurosci       Date:  1998-11-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.